Literature DB >> 16555722

Oligonucleotide IMT504 induces an immunogenic phenotype and apoptosis in chronic lymphocytic leukemia cells.

Juan M Rodriguez1, Fernanda Elias, Alejandro Montaner, Juan Flo, Ricardo A Lopez, Jorge Zorzopulos, Raul J Franco, Silvina P Lenial, Mariella Lopez Salón, Maria L Pirpignani, Jorge Solimano, Guy Garay, Dardo Riveros, Jose Fernandez, Roberto Cacchione, Juan Dupont.   

Abstract

Oligonucleotides (ODNs) of the PyNTTTTGT class directly stimulate B lymphocytes and plasmacytoid dendritic cells of the immune system of primates. Here we investigated the ability of the PyNTTTTGT ODN prototype IMT504 to regulate the expression of surface molecules and apoptosis in human B-chronic lymphocytic leukemia (CLL) cells. The surface molecules CD25, CD40, CD80 and CD86 were up-regulated upon incubation of the B-CLL cells with IMT504. Co-stimulation with IL-2 resulted in further up-regulation. IMT504-activated B-CLL cells were also good stimulators of T cells in allogeneic mixed lymphocyte reactions and co-stimulation with IL-2 improved this stimulation capacity. Apoptosis of the B-CLL cells in vitro was also stimulated by incubation with IMT504. In this case, co-stimulation with IL-2 was not significant. Furthermore, B-CLL cells of all the patients studied developed an immunogenic phenotype and entered stimulated apoptosis upon in vitro incubation with IMT504 independently of the mutational status of their IgV(H) genes, becoming a good marker for tumor progression.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16555722

Source DB:  PubMed          Journal:  Medicina (B Aires)        ISSN: 0025-7680            Impact factor:   0.653


  4 in total

1.  Hematopoietic stem cell senescence and cancer therapy-induced long-term bone marrow injury.

Authors:  Lijian Shao; Yingying Wang; Jianhui Chang; Yi Luo; Aimin Meng; Daohong Zhou
Journal:  Transl Cancer Res       Date:  2013-10       Impact factor: 1.241

2.  The novel immunotherapeutic oligodeoxynucleotide IMT504 protects neutropenic animals from fatal Pseudomonas aeruginosa bacteremia and sepsis.

Authors:  Abdullah Chahin; Steven M Opal; Jorge Zorzopulos; David V Jobes; Yazan Migdady; Michelle Yamamoto; Nicholas Parejo; John E Palardy; David L Horn
Journal:  Antimicrob Agents Chemother       Date:  2014-12-15       Impact factor: 5.191

3.  IMT504 blocks allodynia in rats with spared nerve injury by promoting the migration of mesenchymal stem cells and by favoring an anti-inflammatory milieu at the injured nerve.

Authors:  Mailín Casadei; Esteban Fiore; Julia Rubione; Luciana María Domínguez; María Florencia Coronel; Candelaria Leiguarda; Mariana García; Guillermo Mazzolini; Marcelo J Villar; Alejandro Montaner; Luis Constandil; E Alfonso Romero-Sandoval; Pablo R Brumovsky
Journal:  Pain       Date:  2021-09-15       Impact factor: 7.926

4.  Non-clinical safety studies of IMT504, a unique non-CpG oligonucleotide.

Authors:  Raúl Franco; Juan M Rodriguez; Fernanda Elías; Andrés Hernando-Insúa; Juan Fló; Ricardo López; Carlos Nagle; Néstor Lago; Jorge Zorzopulos; David L Horn; Alejandro D Montaner
Journal:  Nucleic Acid Ther       Date:  2014-04-10       Impact factor: 5.486

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.